Search Results

7 results

  1. CORESTA Congress, Kunming, 2018, Agronomy/Phytopathology Groups, APPOST 11

    Field trials with low nicotine tobacco varieties developed by conventional breeding technique: first results

    MALPICA A.(1); EVANS W.(2); ARCHIBALD C.(3); SCOTT L.(4); GARWE D.(5); CHAMANGO A.M.Z.(6); DORLHAC de BORNE F.(7); COLARD S.(8)
    (1) Bergerac Seed and Breeding, Bergerac, France; (2) Imperial Tobacco South Africa Pvt. Ltd, Umhlanga, Durban, South Africa; (3) Alliance One International Services, Camberley, Surrey, U.K.; (4) Universal Leaf Tobacco Co., Richmond, VA, U.S.A.; (5) Tobacco Research Board (TRB), Harare, Zimbabwe; (6) Agricultural Research & Extension Trust (ARET), Lilongwe, Malawi; (7) Imperial Tobacco Limited, Bergerac, France; (8) SEITA - Imperial Brands plc, Paris, France
    In 2015, the World Health Organisation (WHO) Study Group on Tobacco Product Regulation (“TobReg”) issued an advisory note recommending a strategy of reducing nicotine in tobacco to substantially lower levels of 0.4 mg/g. In the U.S., the Food and Drug ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 52

    Biological test procedure for fresh generated cigarette smoke and e-cigarette aerosols under air-liquid interface (ALI) exposure in 24 and 96 multi-well plates

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    Cigarette smoke and e cigarette aerosol contain particulate matter/liquid droplets in the solid phase as well as volatile substances in the gas phase. Both fractions are of potential toxicological relevance and should be considered when assessing ...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 53

    Use of human derived cell lines to increase the biological relevance of cigarette condensate, non-tobacco materials and e-liquids testing

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    The in vitro testing strategy of tobacco products is mainly based on the testing of extracts from cigarette smoke condensates. An accepted industry wide assay battery has been developed over recent years which delivers reliable results for the ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping with ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...
  6. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 18

    Assessment of the so-called “gateway effect” based on electronic vapour product classifications

    VERRON T.(1); CAHOURS X.(1); CERSON L.(2); COLARD S.(1); O’CONNELL G.(3)
    (1) SEITA-Imperial Tobacco, Fleury-les-Aubrais, France; (2) Imperial Tobacco Limited, Bristol, U.K.; (3) Fontem Ventures B.V., Amsterdam, Netherlands
    Since electronic cigarettes (e-cigs) became popular as alternatives to conventional cigarettes, with subsequent market growth amongst smokers, there is currently a debate as to whether e-cigs may be a "gateway" to conventional cigarette smoking ...